To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
251 Current news
rss
New hope in fight against multi-resistant germs
International antibiotics study: HZI receives €6m funding
14-02-2013
pharmaceutical company GlaxoSmithKline, is still known by its rather cryptic working name, GSK1322322. In the course of clinical trials to evaluate new drugs, physicians typically end up with large numbers...
Priaxon enters collaboration with GSK on Protein-Protein-Interactions
10-01-2013
Priaxon announced a collaboration with GlaxoSmithKline (GSK) to research and develop small molecule modulators of protein-protein-interactions. Priaxon will provide its innovative and proprietary...
GlaxoSmithKline wins top prize at IChemE Awards
07-11-2012
GlaxoSmithKline clinched the top prize at the IChemE 2012 Awards in recognition of its radical change in the manufacture of pharmaceuticals. The organisation won the Outstanding Achievement...
Prosensa Announces Progress on Exon Skipping Compounds for the Treatment of Duchenne Muscular Dystrophy
£10m in milestone payments received from GlaxoSmithKline
24-10-2012
Prosensa has selected clinical candidates for two more compounds for the treatment of Duchenne muscular dystrophy (DMD) and has been granted orphan drug designation for two additional DMD compounds in its pipeline.Prosensa identified suitable oligonucleotide candidates for PRO052 and PRO055, ...
Ablynx proposes to strengten its board
28-09-2012
in research and development, business development and commercial operations. He spent the majority of his career at GlaxoSmithKline, where he held a number of positions including GSK's President...
TiGenix appoints chairman and member of board of directors
21-09-2012
Executive Team of GlaxoSmithKline (GSK), and Chairman and President of GSK Biologicals in Wavre, Belgium, which he built into a world leader in vaccines. He currently serves as Chairman of BESIX, IBA...
Abbott to Collaborate with Astellas in CMV Vaccine Trial
10-09-2012
that Abbott has announced in the last 12 months with a leading pharmaceutical company. Recent collaborations with Pfizer, GlaxoSmithKline and Merck focus on the development of companion diagnostic tests for use...
Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
28-08-2012
Janssen Biologics announced it has initiated the Phase 3 development program for sirukumab (CNTO 136) as part of a collaboration with GlaxoSmithKline plc (GSK). Sirukumab is a human anti...
MEK Inhibitors: A New Weapon in the Fight Against Melanoma
25-06-2012
this pathway, MEK inhibitors (MEKi’s) may be able to combat resistance to BRAF inhibitors.At the 2012 ASCO annual meeting, data was presented from GlaxoSmithKline’s (GSK) Phase I/II clinical trial evaluating...
KineMed Announces Biomarker Discovery Collaboration with GSK
KineMed, Inc. enters multi-year agreement with GlaxoSmithKline to develop kinetic biomarkers
22-06-2012
KineMed, Inc. announced a multi-year R&D collaboration with GlaxoSmithKline plc (GSK) that will apply KineMed’s proprietary biomarker discovery platform in therapeutic areas of interest to GSK...
Netmeeting
